Compare Prudential PLC (PUK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs 10X Genomics Inc — how do they compare? Prudential PLC trades at $23.88 (market cap $28.84B), while 10X Genomics Inc trades at $82.09 (market cap $10.07B). The key difference: Prudential PLC is far larger — about 2.9× 10X Genomics Inc's market cap, and Prudential PLC pays a 2.33% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and 10X Genomics Inc for 92 Days on average.
| PUK | TXG | |
|---|---|---|
Market Cap | $28.84B | $10.07B |
Volume | 3,531,298 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $33.61 | $97.74 |
52-Week Low | $23.54 | $11.48 |
Typical Hold Time | 119 Days | 92 Days |
Enterprise Value | $28.38B | $9.59B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.54, down 4.31% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent news highlights strategic moves including the sale of its Alexforbes stake and a rebranding of its wealth management unit. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook is mixed: solid fundamentals and growth initiatives support upside, but technical weakness and earnings volatility pose risks. Investment opportunity lies in the attractive valuation (P/E 8.4) and strategic focus, countered by bearish momentum and competitive pressures in insurance markets.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
